Zum Inhalt

Breast Cancer Research and Treatment

Ausgabe 2/2017

Inhalt (33 Artikel)

Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients

  • Open Access
  • Review

Muneer Ahmed, F. Jozsa, R. Baker, I. T. Rubio, J. Benson, M. Douek

Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature

  • Review

Fausto Petrelli, Gianluca Tomasello, Sandro Barni, Veronica Lonati, Rodolfo Passalacqua, Michele Ghidini

Does obesity modify the relationship between physical activity and breast cancer risk?

  • Review

S. E. Neil-Sztramko, T. Boyle, E. Milosevic, S. F. Nugent, C. C. Gotay, K. L. Campbell

Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast

  • Preclinical study

Fanfan Meng, Bingbing Liu, Gan Xie, Yawen Song, Xia Zheng, Xiaolong Qian, Shuai Li, Hongqin Jia, Xinmin Zhang, Lanjing Zhang, Yi-ling Yang, Li Fu

Therapeutic blockade of Foxp3 in experimental breast cancer models

  • Preclinical study

Mariela A. Moreno Ayala, María Florencia Gottardo, Mercedes Imsen, Antonela S. Asad, Elisa Bal de Kier Joffé, Noelia Casares, Juan José Lasarte, Adriana Seilicovich, Marianela Candolfi

Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer

  • Preclinical Study

Cecilia L. Speyer, Miriam A. Bukhsh, Waris S. Jafry, Rachael E. Sexton, Sudeshna Bandyopadhyay, David H. Gorski

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study

  • Preclinical study

Toni Roeke, Marcelo Sobral-Leite, Tim J. A. Dekker, Jelle Wesseling, Vincent T. H. B. M. Smit, Rob A. E. M. Tollenaar, Marjanka K. Schmidt, Wilma E. Mesker

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

  • Preclinical study

Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M. Banks, Bryce Portier, Anil V. Parwani, Zaibo Li

Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan

  • Open Access
  • Clinical trial

M. J. Fischer, K. Inoue, A. Matsuda, J. R. Kroep, S. Nagai, K. Tozuka, M. Momiyama, N. I. Weijl, D. Langemeijer-Bosman, S. R. S. Ramai, J. W. R. Nortier, H. Putter, K. Yamaoka, K. Kubota, K. Kobayashi, A. A. Kaptein

Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy

  • Clinical Trial

Young-Joon Kang, Wonshik Han, Soojin Park, Ji Young You, Ha Woo Yi, Sungmin Park, Sanggeun Nam, Joo Heung Kim, Keong Won Yun, Hee Jeong Kim, Sei Hyun Ahn, Seho Park, Jeong Eon Lee, Eun Sook Lee, Dong-Young Noh, Jong Won Lee

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial

  • Clinical trial

Qamar J. Khan, Bruce F. Kimler, Pavan S. Reddy, Priyanka Sharma, Jennifer R. Klemp, Jennifer L. Nydegger, Hung-Wen Yeh, Carol J. Fabian

Clinical implementation of synthesized mammography with digital breast tomosynthesis in a routine clinical practice

  • Clinical trial

Phoebe E. Freer, Joanna Riegert, Laura Eisenmenger, Dominik Ose, Nicole Winkler, Matthew A. Stein, Gregory J. Stoddard, Rachel Hess

Impact of pathologic diagnosis of internal mammary lymph node metastasis in clinical N2b and N3b breast cancer patients

  • Clinical trial

Ji Hyeon Joo, Su Ssan Kim, Seung-Do Ahn, Eun Kyung Choi, Jin Hong Jung, Yuri Jeong, Sei Hyun Ahn, Byung Ho Son, Jong Won Lee, Hee Jung Kim, Beom Seok Go, Hak Hee Kim, Joo Hee Cha, Hee Jung Shin, Eun Young Chae

Long-term peripheral neuropathy symptoms in breast cancer survivors

  • Clinical trial

Moaath Mustafa Ali, Machelle Moeller, Lisa Rybicki, Halle C. F. Moore

IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer

  • Open Access
  • Clinical trial

Carlo Palmieri, Richard Szydlo, Marie Miller, Laura Barker, Neva H. Patel, Hironobu Sasano, Tara Barwick, Henry Tam, Dimitri Hadjiminas, Jasmin Lee, Abeer Shaaban, Hanna Nicholas, R. Charles Coombes, Laura M. Kenny

Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study

  • Clinical trial

Anne Blaes, Heather Beckwith, Natalia Florea, Robert Hebbel, Anna Solovey, David Potter, Douglas Yee, Rachel Vogel, Russell Luepker, Daniel Duprez

Association between survival time with metastatic breast cancer and aggressive end-of-life care

  • Epidemiology

Melissa K. Accordino, Jason D. Wright, Sowmya Vasan, Alfred I. Neugut, Tal Gross, Grace C. Hillyer, Dawn L. Hershman

FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women?

  • Epidemiology

Allyson C. Espinal, Matthew F. Buas, Dan Wang, David Ting-Yuan Cheng, Lara Sucheston-Campbell, Qiang Hu, Li Yan, Rochelle Payne-Ondracek, Eduardo Cortes, Li Tang, Zhihong Gong, Gary Zirpoli, Thaer Khoury, Song Yao, Angela Omilian, Kitaw Demissie, Elisa V. Bandera, Song Liu, Christine B. Ambrosone, Michael J. Higgins

Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients

  • Epidemiology

Ke Zheng, Jin-Xiang Tan, Fan Li, Yu-Xian Wei, Xue-Dong Yin, Xin-Liang Su, Hong-Yuan Li, Qi-Lun Liu, Bin-Lin Ma, Jiang-Hua Ou, Hui Li, Sui-Sheng Yang, Ai-Mei Jiang, Qing Ni, Jian-Lun Liu, Jin-Ping Liu, Hong Zheng, Zhang-Jun Song, Ling Wang, Jian-Jun He, Tian-Ning Zou, Jun Jiang, Guo-Sheng Ren

Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004–2013

  • Epidemiology

Yasuaki Sagara, Rachel A. Freedman, Stephanie M. Wong, Fatih Aydogan, Anvy Nguyen, William T. Barry, Mehra Golshan

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

  • Open Access
  • Epidemiology

Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones

  • Epidemiology

Yiwey Shieh, Donglei Hu, Lin Ma, Scott Huntsman, Charlotte C. Gard, Jessica W. T. Leung, Jeffrey A. Tice, Elad Ziv, Karla Kerlikowske, Steven R. Cummings

Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study

  • Epidemiology

Megan A. Healey, Kelly A. Hirko, Andrew H. Beck, Laura C. Collins, Stuart J. Schnitt, A. Heather Eliassen, Michelle D. Holmes, Rulla M. Tamimi, Aditi Hazra

Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?

  • Brief Report

Arti R. Jonna, Kenny Q. Sam, Lilian O. Ebuoma, Emily L. Sedgwick, Tao Wang, Ana P. Benveniste

Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women

  • Brief Report

Carole Corsini, Sarra Henouda, Dalel Ben Nejima, Héléna Bertet, Alain Toledano, Hamouda Boussen, Faouzi Habib, Asma Mouhout, Ahmed Gaballah, Hesham El Ghazaly, Céline Bourgier, Isabelle Coupier, Virginie Galibert, Karen Baudry, Paul Vilquin, Louise Biquard, Jean-Marc Rey, Yazid Belkacemi, Paul Ihout, David Khayat, Marie-Christine Picot, Assia Bensalem, Pascal Pujol

NanoString-based breast cancer risk prediction for women with sclerosing adenosis

  • Open Access
  • Brief Report

Stacey J. Winham, Christine Mehner, Ethan P. Heinzen, Brendan T. Broderick, Melody Stallings-Mann, Aziza Nassar, Robert A. Vierkant, Tanya L. Hoskin, Ryan D. Frank, Chen Wang, Lori A. Denison, Celine M. Vachon, Marlene H. Frost, Lynn C. Hartmann, E. Aubrey Thompson, Mark E. Sherman, Daniel W. Visscher, Amy C. Degnim, Derek C. Radisky

Reply to Kopans

  • Letter to the Editor

Steven A. Narod

Rebuttal comments

  • Rebuttal Letter

Daniel B. Kopans

Neu im Fachgebiet Onkologie

Darmkrebsresektion: Laparoskopisches Vorgehen gerade auch für Gebrechliche

Daten aus Großbritannien legen nahe, dass insbesondere ältere und gebrechlichere Darmkrebspatientinnen und -patienten von einem minimalinvasiven Eingriff profitieren könnten – ihnen dieser aber allzu häufig vorenthalten wird.   

TNBC: Sacituzumab Govitecan verlängert das PFS

Sacituzumab Govitecan ist als Therapieoption beim vorbehandelten, fortgeschrittenen triple-negativen Brustkrebs (TNBC) etabliert. In Kombination mit Pembrolizumab konnte der Wirkstoff nun auch bei zuvor unbehandelten Tumoren seine Wirksamkeit belegen.

Therapie von Oligometastasen verbessert Prognose bei Prostata-Ca.

Die operative Entfernung oder Bestrahlung von Oligometastasen eines Prostatakarzinoms verlängert das progressionsfreie Überleben deutlich, der Effekt auf das Gesamtüberleben bleibt jedoch unklar.

Wie häufig sind radiologische Progressionen ohne PSA-Wert-Anstieg?

Radiologische Progressionen ohne vorherige PSA-Wert-Erhöhungen sind mit 10% recht häufig. Dafür sprechen zumindest Ergebnisse einer explorativen Reanalyse von Daten aus der australisch-neuseeländischen ENZAMET-Studie.   

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Bildnachweise
Laparoskopische Rektumresektion/© Springer Medizin Verlag GmbH, Infusion über Armvene/© Seventyfour / stock.adobe.com (Symbolbild mit Fotomodell) , Stereotaktische Strahlentherapie (SBRT) einer solitären ossären Metastase in dem Brustwirbelkörper/© Springer Medizin Verlag GmbH, Arzt klärt urologischen Patient auf/© RFBSIP / stock.adobe.com (Symbolbild mit Fotomodellen)